Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Bullboard Posts
Comment by mtvrdonon Mar 09, 2017 3:49pm
97 Views
Post# 25959665

RE:NO FDA APPROVAL ON ONE SIDE OF HEART

RE:NO FDA APPROVAL ON ONE SIDE OF HEARTThey started, historically, with the right ventricle because they were interested in diagnosing pediatric and newborn conditions.  Most congenital defects and newborn heart conditions involve the right ventricle.  They did well clinically with that application, but it's a relatively specialized market if you're looking at the business model..

The clinical successfulness of that application and the business need to expand their sales base led to adding modelling of the Atria and left ventrical.   They've work on the technology for that for a while now and the Health Canada approval was for the full heart application.  With the full heart technology, they can sell to pretty every hospital and cardiac clinic in Canada which is a big new sales base.   They are also allowed to sell in a number of other countries.   They have CE Mark and FDA for the RV technolgy and are working on CFDA (Chinese) for the full heart through their partner.   One place they can sell already is Hong Kong and that ties in with Chinese plans. 
Bullboard Posts